Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) filed an 8-K current report with the Securities and Exchange Commission on August 6, 2026, disclosing a material corporate event under accession number 0001193125-26-338022. The Canton, Massachusetts-based company operates in the regenerative medicine and advanced wound care sector, developing and commercializing human cell- and tissue-based products for wound management and surgical biologics applications. Organogenesis became a publicly traded entity through a de-SPAC business combination in 2018 and has remained listed on Nasdaq since completing that transaction. The company serves healthcare providers across the United States with products designed to support tissue regeneration. For full filing details, deal history, and comprehensive SPAC data on ORGO and hundreds of other transactions, sign up for SpacDesk.